Introduction
Novel oral anticoagulants and antiplatelet agents will have a profound impact
on the antithrombotics market. expects Bayer rivaroxaban and Sankyo/Eli Lilly
prasugrel to achieve blockbuster status. Parenteral anticoagulants are not
expected to be large revenue generators, due to low clinical unmet need in
this market segment and strong competition from current gold standard agents.
Scope
- Event-driven sales projections for 2007-16 for key late-stage
developmental antithrombotics in the seven major markets
- Commercial analysis of late-stage developmental compounds in terms of
their ability to satisfy unmet clinical needs
- An overview of the antithrombotics R&D pipeline with a comprehensive
assessment of all classes in development
- Analysis of the potential for developmental antithrombotics with respect
to the patient populations for which they are indicated
Report Highlights
Following the abrupt withdrawal of AstraZeneca Exanta in February 2006, Bayer
Healthcare rivaroxaban and Boehringer Ingelheim Rendix are well positioned to
profit from patients switching from warfarin, and market growth obtained by
recruiting the previously untreated population.
The highest selling brands in the antidiabetics market are Lovenox
(enoxaparin) and Plavix (clopidogrel), but these agents will be genericized
within our forecast period. Consequently, pipeline agents are expected to
become significant drivers in the market.
Acute Coronary Syndrome is usually the first indication for which novel
anticoagulants are approved; this is a quick route to market, while drug
companies then prepare to launch their products in more lucrative, chronic
treatment markets.
Reasons to Purchase
- Understand the factors that will drive the success of next-generation
antithrombotics
- Overcome the barriers to entry generated by lifecycle strategies of key
players in the market
- Assess the remaining market opportunity, where established therapies and
other developmental compounds fail to address key unmet clinical needs
View Cart
